Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 430Neoplasms 284Carcinoma, Non-Small-Cell Lung 266Colorectal Neoplasms 228Lung Neoplasms 173Prostatic Neoplasms 171Carcinoma, Hepatocellular 156Stomach Neoplasms 129Leukemia, Myeloid, Acute 118Pancreatic Neoplasms 115Multiple Myeloma 105Recurrence 96Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 88Neoplasm Metastasis 87Rectal Neoplasms 85Ovarian Neoplasms 77Triple Negative Breast Neoplasms 75Small Cell Lung Carcinoma 72Head and Neck Neoplasms 68Brain Neoplasms 68Esophageal Neoplasms 64Glioblastoma 63Colonic Neoplasms 60Endometrial Neoplasms 58Melanoma 54Hematologic Neoplasms 53Motor Activity 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Nasopharyngeal Carcinoma 46

Interventions

trifluridine tipiracil drug combination 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × mCRC × Clear all
NCT07543471 2026-04-24

PK similarity

Shanghai Henlius Biotech

Phase 1 Not yet recruiting
387 enrolled

mCRC

NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Jinan Central Hospital

Phase 2 Not yet recruiting
37 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡